Toth Financial Advisory Corp lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.0% during the 1st quarter, HoldingsChannel reports. The fund owned 12,984 shares of the medical research company’s stock after selling 132 shares during the quarter. Toth Financial Advisory Corp’s holdings in Amgen were worth $2,467,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Weybosset Research & Management LLC raised its holdings in shares of Amgen by 11.9% in the 1st quarter. Weybosset Research & Management LLC now owns 1,875 shares of the medical research company’s stock valued at $356,000 after acquiring an additional 200 shares in the last quarter. Portland Global Advisors LLC raised its holdings in shares of Amgen by 0.8% in the 1st quarter. Portland Global Advisors LLC now owns 15,059 shares of the medical research company’s stock valued at $2,861,000 after acquiring an additional 122 shares in the last quarter. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in shares of Amgen by 55.9% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 725 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 260 shares in the last quarter. CRA Financial Services LLC raised its holdings in shares of Amgen by 5.6% in the 1st quarter. CRA Financial Services LLC now owns 1,165 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares in the last quarter. Finally, Cascade Investment Advisors Inc. raised its holdings in shares of Amgen by 1.1% in the 1st quarter. Cascade Investment Advisors Inc. now owns 7,100 shares of the medical research company’s stock valued at $1,349,000 after acquiring an additional 75 shares in the last quarter. 80.65% of the stock is currently owned by hedge funds and other institutional investors.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the sale, the director now owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 6,000 shares of company stock valued at $1,115,580 in the last ninety days. 0.25% of the stock is currently owned by corporate insiders.

Shares of AMGN opened at $169.87 on Thursday. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53. Amgen, Inc. has a one year low of $166.30 and a one year high of $210.19. The firm has a market capitalization of $102.23 billion, a P/E ratio of 11.80, a PEG ratio of 2.21 and a beta of 1.15.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the previous year, the company posted $3.47 earnings per share. Amgen’s revenue was up .1% compared to the same quarter last year. Equities research analysts predict that Amgen, Inc. will post 13.93 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.41%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.

Several research firms have weighed in on AMGN. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a report on Friday, April 5th. JPMorgan Chase & Co. reissued a “hold” rating and set a $190.00 price objective on shares of Amgen in a report on Wednesday. Mizuho set a $208.00 price objective on Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Finally, BidaskClub cut Amgen from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus price target of $208.84.

COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Holdings Decreased by Toth Financial Advisory Corp” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://theolympiareport.com/2019/05/16/amgen-inc-amgn-holdings-decreased-by-toth-financial-advisory-corp.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.